SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totaling 339 shares, a decrease of 73.4% from the April 15th total of 1,276 shares. Based on an average trading volume of 7,336 shares, the days-to-cover ratio is presently 0.0 days.
SAB Biotherapeutics Price Performance
Shares of SABSW stock traded up $0.00 on Friday, hitting $0.02. 1,111 shares of the company’s stock were exchanged, compared to its average volume of 22,053. SAB Biotherapeutics has a 12 month low of $0.02 and a 12 month high of $0.18. The company has a 50 day moving average of $0.03 and a 200 day moving average of $0.03.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Featured Stories
- Five stocks we like better than SAB Biotherapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
